INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 56 filers reported holding INOZYME PHARMA INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,572,858 | -54.6% | 1,326,871 | -39.9% | 0.00% | -50.0% |
| Q2 2023 | $12,288,300 | +126714.2% | 2,206,158 | +30.5% | 0.01% | 0.0% |
| Q1 2023 | $9,690 | +2995.8% | 1,691,075 | +467.6% | 0.01% | – |
| Q4 2022 | $313 | -99.9% | 297,936 | +75.1% | 0.00% | – |
| Q3 2022 | $456,000 | -44.8% | 170,184 | -1.7% | 0.00% | -100.0% |
| Q2 2022 | $826,000 | +507.4% | 173,092 | +767.5% | 0.00% | – |
| Q4 2021 | $136,000 | +6.2% | 19,952 | +80.3% | 0.00% | – |
| Q3 2021 | $128,000 | -87.8% | 11,064 | -82.0% | 0.00% | -100.0% |
| Q2 2021 | $1,045,000 | -64.6% | 61,313 | -58.9% | 0.00% | -50.0% |
| Q1 2021 | $2,954,000 | +179.7% | 149,205 | +271.5% | 0.00% | +100.0% |
| Q3 2020 | $1,056,000 | – | 40,164 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |